These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 35066461)

  • 21. Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US.
    Kleinman RA
    JAMA Psychiatry; 2020 Nov; 77(11):1163-1171. PubMed ID: 32667648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont.
    Clemans-Cope L; Wishner JB; Allen EH; Lallemand N; Epstein M; Spillman BC
    J Subst Abuse Treat; 2017 Dec; 83():27-35. PubMed ID: 29129193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
    Jones CM; Campopiano M; Baldwin G; McCance-Katz E
    Am J Public Health; 2015 Aug; 105(8):e55-63. PubMed ID: 26066931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology of emergency department visits for opioid overdose: a population-based study.
    Hasegawa K; Brown DF; Tsugawa Y; Camargo CA
    Mayo Clin Proc; 2014 Apr; 89(4):462-71. PubMed ID: 24629443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age differences in heroin and prescription opioid abuse among enrolees into opioid treatment programs.
    Cleland CM; Rosenblum A; Fong C; Maxwell C
    Subst Abuse Treat Prev Policy; 2011 Jun; 6():11. PubMed ID: 21635762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont.
    Mohlman MK; Tanzman B; Finison K; Pinette M; Jones C
    J Subst Abuse Treat; 2016 Aug; 67():9-14. PubMed ID: 27296656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the fentanyl patch-for-patch program in Ontario, Canada.
    Tadrous M; Greaves S; Martins D; Nadeem K; Singh S; Mamdani MM; Juurlink DN; Gomes T
    Int J Drug Policy; 2019 Apr; 66():82-86. PubMed ID: 30743092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.
    Fox L; Nelson LS
    CNS Drugs; 2019 Dec; 33(12):1147-1154. PubMed ID: 31552608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
    Davis CS; Carr D
    Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013.
    Taylor CA; Bell JM; Breiding MJ; Xu L
    MMWR Surveill Summ; 2017 Mar; 66(9):1-16. PubMed ID: 28301451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. State variation in opioid treatment policies and opioid-related hospital readmissions.
    Blanchard J; Weiss AJ; Barrett ML; McDermott KW; Heslin KC
    BMC Health Serv Res; 2018 Dec; 18(1):971. PubMed ID: 30558595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Medicaid Expansion and Rates of Opioid-Related Hospital Use.
    Wen H; Soni A; Hollingsworth A; Freedman S; Benitez J; Simon K; Saloner B
    JAMA Intern Med; 2020 May; 180(5):753-759. PubMed ID: 32202609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impacts of Regulations on Air Quality and Emergency Department Visits in the Atlanta Metropolitan Area, 1999-2013.
    Russell AG; Tolbert P; Henneman L; Abrams J; Liu C; Klein M; Mulholland J; Sarnat SE; Hu Y; Chang HH; Odman T; Strickland MJ; Shen H; Lawal A
    Res Rep Health Eff Inst; 2018 Apr; 2018(195):1-93. PubMed ID: 31883240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
    Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
    J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns and predictors of opioid use among migraine patients at emergency departments: A retrospective database analysis.
    Shao Q; Rascati KL; Lawson KA; Wilson JP
    Cephalalgia; 2020 Nov; 40(13):1489-1501. PubMed ID: 32781832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geographic variation in availability of opioid treatment programs across U.S. communities.
    Jehan S; Zahnd WE; Wooten NR; Seay KD
    J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asthma Surveillance - United States, 2006-2018.
    Pate CA; Zahran HS; Qin X; Johnson C; Hummelman E; Malilay J
    MMWR Surveill Summ; 2021 Sep; 70(5):1-32. PubMed ID: 34529643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.
    Yedinak JL; Goedel WC; Paull K; Lebeau R; Krieger MS; Thompson C; Buchanan AL; Coderre T; Boss R; Rich JD; Marshall BDL
    PLoS Med; 2019 Nov; 16(11):e1002963. PubMed ID: 31743335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.